Capital Group Buy: Micro ID & Susceptibility Testing
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide.
By pioneering diagnostic solutions, we help clinicians improve patient care and we help industries prevent contamination of the food and pharmaceuticals they produce. At bioMérieux we are convinced that, only by taking into account our entire ecosystem and the public interest, will we be able to succeed in building a healthier world and a more inclusive society.
Group Buy Details
- Premier Contract: PP-LA-543
- Contract Category: Automated Microbial Identification and Susceptibility Analyzers
- Start Date:
- End Date:
- All shipments must be received by member by November 30, 2023